Deals: Page
-
Courtesy of Astellas
Astellas takes stake in gene therapy developer Taysha
Already an investor in gene therapy, the Japanese pharma will buy 15% of the Texas biotech’s stock and gain options to two gene therapies for central nervous system disorders.
By Delilah Alvarado • Oct. 24, 2022 -
Elizabeth Regan/BioPharma Dive
Myovant agrees to sell after buyer ups price
Sumitomo Pharma, a Japanese drug company that already owns 52% of Myovant, is now offering to buy all the remaining shares for $27 apiece in a deal that values the biotech at $2.9 billion.
By Jacob Bell • Oct. 24, 2022 -
Getty Images
AGTC yields to biotech downturn with gene therapy buyout deal
The biotech is the latest in a growing list of genetic medicine developers to sell themselves near record stock lows amid a challenging funding environment.
By Ben Fidler • Oct. 24, 2022 -
AbbVie to buy UK biotech DJS for $255M
The deal gives AbbVie an experimental medicine for idiopathic pulmonary fibrosis, as well as a platform for designing antibody drugs that can target proteins known as GPCRs.
By Ned Pagliarulo • Oct. 20, 2022 -
Mario Tama via Getty Images
J&J, flush with cash, says high valuations remain a dealmaking hurdle
“We don’t have to do anything out of desperation,” said CFO Joseph Wolk on J&J’s second quarter earnings call. J&J holds $34 billion in cash and other liquid assets.
By Christopher Newman • Oct. 18, 2022 -
Getty Images
Aveo sells to LG Chem after turnaround for kidney cancer drug
The biotech survived multiple drug rejections, shareholder lawsuits and a federal investigation before winning approval of Fotivda, the centerpiece of its $566 million buyout on Tuesday.
By Ben Fidler • Oct. 18, 2022 -
Courtesy of Eli Lilly
Lilly bets more than $600M on a gene therapy developer targeting hearing loss
Like with Prevail Therapeutics, Lilly’s first gene therapy acquisition, the pharma’s planned buyout of Akouos includes a contingent value right that could hike the deal’s overall cost.
By Jacob Bell • Oct. 18, 2022 -
Michael M. Santiago via Getty Images
Enliven to enter public markets through reverse merger with Imara
With the IPO market still depleted, Enliven, a precision oncology company, has found a different path to the Nasdaq stock exchange.
By Jacob Bell • Oct. 14, 2022 -
PureTech, Nektar end talks of combination
Days after acknowledging that discussions were taking place, the two companies have called off further negotiations over a possible deal, leaving Nektar’s future again uncertain.
By Jonathan Gardner • Updated Oct. 11, 2022 -
Permission granted by Incyte
Incyte, branching out in dermatology, to buy startup Villaris
The acquisition, Incyte’s first of an entire company, hands the pharmaceutical company a potentially long lasting treatment for the skin disease vitiligo.
By Gwendolyn Wu • Oct. 3, 2022 -
Spencer Platt via Getty Images
Myovant rejects $2.4B buyout offer from Japanese majority owner
The biotech said the proposed offer “significantly undervalues” the company, but that it’s open to considering a higher bid.
By Christopher Newman • Oct. 3, 2022 -
Lisa Maree Williams via Getty Images
AstraZeneca to acquire gene editing biotech LogicBio
Shares in LogicBio had lost nearly all their value since a 2018 IPO, bringing the company to the brink of Nasdaq delisting. The buyout deal represents a premium of over 600%.
By Delilah Alvarado • Oct. 3, 2022 -
Getty Images
Solid Bio yields to Sarepta on Duchenne with plans for merger, R&D shakeup
The biotech, which fell behind Sarepta in developing a Duchenne gene therapy, will merge with AavantiBio, a startup run by a former Sarepta executive.
By Ben Fidler • Sept. 30, 2022 -
Permission granted by Ventus Therapeutics
Ventus sells its lead drug candidate to Novo Nordisk
The biotech will part with its lead drug candidate, an anti-inflammatory small molecule, in Novo Nordisk’s bet on inflammasome treatments.
By Gwendolyn Wu • Sept. 29, 2022 -
Peddalanka Ramesh Babu via Getty Images
Roche pays $70M in another bid to catch up on cancer cell therapies
Rival companies have set a standard in lymphoma and leukemia. Now the Swiss drugmaker wants to be a pioneer in cell treatments for solid tumors.
By Jonathan Gardner • Sept. 27, 2022 -
Permission granted by Seagen
Seagen, amid deal rumors, spends $50M on a dual-targeting cancer drug
While a long-rumored acquisition by Merck & Co. still hasn’t materialized, Seagen is forging ahead with a deal of its own, grabbing rights to a bispecific antibody drug from Lava Therapeutics.
By Jacob Bell • Sept. 26, 2022 -
Getty Images
AstraZeneca gives up on Ionis’ RNA drug for heart disease
The British drugmaker decided the medicine, which works similarly to Novartis’s Leqvio, wasn’t potent enough to justify further testing.
By Jonathan Gardner • Sept. 23, 2022 -
Getty Images
Cell therapy startup Carisma merges with troubled Sesen in bid for Wall Street
The deal results from a strategic review Sesen, formerly known as Eleven Biotherapeutics, undertook after the FDA rejected its top drug last year.
By Gwendolyn Wu • Sept. 21, 2022 -
Getty Images
Rocket gives struggling gene therapy company a lifeline after SPAC merger
Rocket is acquiring Renovacor at a roughly 75% discount to its public debut price last year, when it became one of dozens of biotechs to merge with a blank check company, or SPAC.
By Ben Fidler • Sept. 20, 2022 -
Getty Images
GenFit, continuing rebuild, buys startup Versantis
The French company, still aiming to rebound from a Phase 3 study failure two years ago, will pay about $41 million for Versantis and its experimental liver disease drugs.
By Delilah Alvarado • Sept. 19, 2022 -
Getty Images
Theravance, flush with royalty cash, buys shares from GSK
The planned transaction will further unwind the respiratory disease company’s relationship with GSK, which dates back two decades.
By Jonathan Gardner • Sept. 19, 2022 -
Getty Images
After safety setbacks, job cuts, Imara sells its top drug to a startup
The biotech, which has lost nearly all of its value since going public in 2020, reached a deal to sell a drug it tested in sickle cell disease to Cardurion Pharmaceuticals, a richly funded company focused on cardiovascular research.
By Kristin Jensen • Sept. 8, 2022 -
Roche to pay $250M for Good Therapeutics and its targeted drug technology
The team behind the Seattle-based startup will launch a new company, Bonum Therapeutics, after the sale to Roche is completed.
By Kristin Jensen • Sept. 7, 2022 -
Courtesy of Illumina
Illumina’s hold on Grail depends now on separate appeals in US, Europe
While it plans to appeal this week’s EC decision, Illumina say it’s preparing for ‘strategic alternatives’ to its acquisition of early cancer detection firm Grail.
By Elise Reuter • Updated Sept. 6, 2022 -
Courtesy of Grail
Judge rules in favor of Illumina, countering FTC concerns over Grail merger
The ruling makes it more likely Illumina can retain its former subsidiary, which makes cancer diagnostics. The dispute is an important test case for the agency’s plans to more closely scrutinize life sciences mergers.
By Elise Reuter , Ricky Zipp • Sept. 2, 2022
Previous
